Home / Private raises / Lexaria Bioscience Corp.
Lexaria Bioscience Corp.
Biotechnology · Kelowna, British Columbia, Canada · $113K sold across 1 offering
Form D filings (1)
| Filed | Form | Sold | Offered | Investors | Exemption | Securities | First sale | |
|---|---|---|---|---|---|---|---|---|
| 2026-09-21 | D (new) | $113K | $113K | 3 | 506(b) | Options/warrants | Sep 9 | SEC ↗ |
An update (D/A) restates the running total of its offering, so the total above counts each offering's latest figure once.
Sold through (placement agents)
| Broker-dealer | Solicited in |
|---|---|
| H.C. WAINWRIGHT & CO. | — |
Sales commissions $8K in the latest filing.
Issuer
| Industry | Biotechnology |
| Located | Kelowna, British Columbia, Canada |
| Entity | Corporation |
| Incorporated | Nevada |
| Revenue range | $5,000,001 - $25,000,000 |
| SEC CIK | 1348362 |
People named in the latest filing
| Name | Role |
|---|---|
| Christopher Bunka | Director |
| John Docherty | Executive Officer, Director |
| Richard Christopher | Executive Officer, Director |
| Michael Shankman | Executive Officer |
| Nicholas Baxter | Director |
| William Edward McKechnie | Director |
| ALBERT REESE | Director |
| Bal Bhullar | Director |
Names and roles as filed with the SEC. Addresses are not shown.
Source: SEC EDGAR Form D filings. Amounts are self-reported by the issuer. Not investment advice.
How are we doing?
